Centre for Reviews and Dissemination (CRD), University of York, York, UK.
Health Technol Assess. 2010 Jul;14(37):1-288. doi: 10.3310/hta14370.
Photodynamic therapy (PDT) is the use of a light-sensitive drug, in combination with light of a visible wavelength, to destroy target cells. PDT is used either as a primary treatment or as an adjunctive treatment. It is fairly well accepted in clinical practice for some types of skin cancer but has yet to be fully explored as a treatment for other forms of cancer.
To systematically review the clinical effectiveness and safety of PDT in the treatment of Barrett's oesophagus, pre-cancerous skin conditions and the following cancers: biliary tract, brain, head and neck, lung, oesophageal and skin.
The search strategy included searching electronic databases (between August and October 2008), followed by update searches in May 2009, along with relevant bibliographies, existing reviews, conference abstracts and contact with experts in the field.
Randomised controlled trials (RCTs) in skin conditions and Barrett's oesophagus, non-randomised trials for all other sites.
People with Barrett's oesophagus, pre-cancerous skin conditions or primary cancer in the following sites: biliary tract, brain, head and neck, lung, oesophageal and skin.
Any type of PDT for either curative or palliative treatment.
Any comparator including differing applications of PDT treatments (relevant comparators varied according to the condition).
The outcomes measured were mortality, morbidity, quality of life, adverse events and resource use.
A standardised data extraction form was used. The quality of RCTs and non-randomised controlled studies was assessed using standard checklists. Data extracted from the studies were tabulated and discussed in a narrative synthesis, and the influence of study quality on results was discussed. Meta-analysis was used to estimate a summary measure of effect on relevant outcomes, with assessment of both clinical and statistical heterogeneity. Two reviewers independently screened all titles and abstracts, and data extracted and quality assessed the trials, with discrepancies resolved by discussion or referral to a third reviewer. A scoping review was also undertaken.
Overall, 88 trials reported in 141 publications were included, with some trials covering more than one condition. For actinic keratosis (AK), the only clear evidence of effectiveness was that PDT appeared to be superior to placebo. For Bowen's disease, better outcomes with PDT were suggested when compared with cryotherapy or fluorouracil. For basal cell carcinoma (BCC), PDT may result in similar lesion response rates to surgery or cryotherapy but with better cosmetic outcomes. For nodular lesions, PDT appeared to be superior to placebo and less effective than surgery but suggestive of better cosmetic outcome. For Barrett's oesophagus, PDT in addition to omeprazole appeared to be more effective than omeprazole alone at long-term ablation of high-grade dysplasia and slowing/preventing progression to cancer. No firm conclusions could be drawn for PDT in oesophageal cancer. Further research into the role of PDT in lung cancer is needed. For cholangiocarcinoma, PDT may improve survival when compared with stenting alone. There was limited evidence on PDT for brain cancer and cancers of the head and neck. A wide variety of photosensitisers were used and, overall, no serious adverse effects were linked to PDT.
There were few well-conducted, adequately powered RCTs, and quality of life (QoL) and resource outcomes were under-reported. Problems were identified with reporting of key study features and quality parameters, making the reliability of some studies uncertain. Methodological limitations and gaps in the evidence base made it difficult to draw firm conclusions.
Evidence of effectiveness was found for PDT in the treatment of AK and nodular BCC in relation to placebo, and possibly for treating Barrett's oesophagus. However, the effectiveness of PDT in relation to other treatments is not yet apparent. High-quality trials are needed to compare PDT with relevant comparators for all meaningful outcomes, including QoL and adverse effects. Further research is also needed on patient experience of PDT, as well as on the cost-effectiveness of PDT.
光动力疗法(PDT)是利用光敏感药物,结合可见波长的光,来破坏靶细胞。PDT 既可以作为主要治疗手段,也可以作为辅助治疗手段。在某些类型的皮肤癌的临床实践中,它已经得到了广泛的应用,但尚未充分探索其在治疗其他类型癌症方面的应用。
系统评价 PDT 在治疗巴雷特食管、癌前皮肤状况以及以下癌症中的临床疗效和安全性:胆道、脑、头颈部、肺、食管和皮肤。
搜索策略包括在 2008 年 8 月至 10 月期间搜索电子数据库,随后在 2009 年 5 月进行更新搜索,同时还搜索了相关的参考文献、现有综述、会议摘要和与该领域专家的联系。
皮肤状况和巴雷特食管的随机对照试验(RCT),其他所有部位的非随机试验。
患有巴雷特食管、癌前皮肤状况或原发性癌症的患者,部位包括胆道、脑、头颈部、肺、食管和皮肤。
任何类型的 PDT,用于根治性或姑息性治疗。
任何对照措施,包括 PDT 治疗的不同应用(根据具体情况,相关对照措施有所不同)。
测量的结局包括死亡率、发病率、生活质量、不良事件和资源利用。
使用标准化的数据提取表。使用标准检查表评估 RCT 和非随机对照研究的质量。从研究中提取的数据进行表格化和叙述性综合,并讨论结果的影响因素。对于相关结局,使用荟萃分析估计效应的综合测量值,并评估临床和统计学异质性。两名评审员独立筛选所有标题和摘要,并提取和评估试验数据,有分歧的地方通过讨论或请第三名评审员解决。还进行了范围综述。
总共纳入了 88 项试验,这些试验分别报告在 141 篇出版物中,其中一些试验涵盖了不止一种疾病。对于光化性角化病(AK),唯一明确的疗效证据是 PDT 似乎优于安慰剂。对于 Bowen 病,与冷冻疗法或氟尿嘧啶相比,PDT 有更好的疗效。对于基底细胞癌(BCC),PDT 可能与手术或冷冻疗法的病变反应率相似,但美容结局更好。对于结节性病变,PDT 似乎优于安慰剂,疗效不如手术,但美容结局更好。对于巴雷特食管,PDT 联合奥美拉唑似乎比奥美拉唑单独治疗更能有效地长期消融高级别异型增生并减缓/预防癌症进展。对于食管癌,无法得出 PDT 的明确结论。需要进一步研究 PDT 在肺癌中的作用。对于胆管癌,PDT 可能比单独支架置入术更能提高生存率。对于脑癌和头颈部癌症,PDT 的证据有限。使用了各种光敏剂,总体上,PDT 没有与严重不良事件相关联。
有一些设计良好、充分有力的 RCT,但生活质量(QoL)和资源结局的报告不足。一些关键研究特征和质量参数的报告存在问题,使得一些研究的可靠性不确定。证据基础的方法学局限性和差距使得难以得出确凿的结论。
在 AK 和结节性 BCC 与安慰剂的治疗中发现了 PDT 的疗效证据,并且可能在治疗巴雷特食管方面也有疗效。然而,PDT 与其他治疗方法的疗效尚不清楚。需要高质量的试验来比较 PDT 与所有有意义的结局(包括 QoL 和不良反应)的相关对照措施。还需要进一步研究 PDT 对患者的体验,以及 PDT 的成本效益。